Cipla announced that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) to launch Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat mild-to-moderate Covid-19 at high risk of developing severe disease.1
Earlier in the year, Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries (LMICs). The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies.
Cipla’s Cipmolnu will be available at all big pharmacies
Cipla will soon make Cipmolnu 200mg capsules available at all leading pharmacies and Covid-19 treatment centers across the country. The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment Pan India.
Commenting on the launch, Umang Vohra, managing director and global chief executive officer, Cipla, said, “This launch is yet another step in our endeavor to enable access to all treatments in Covid-19 care. We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients.”
